Furthermore, patients with late-stage BRAF mutant cancers were less likely to have a metastasectomy most likely due to the higher incidence of peritoneal involvement, and survival following metastasectomy was significantly shorter for patients with BRAF mutant compared to BRAF wild-type cancers [109]. The gene discussed is BRAF; the disease is cancer.